Search Within

Jedd D Wolchok

Formats
  1. Journal Article (450)
  2. Meeting Abstract (414)
  3. Book Section (19)
  4. Editorial (9)
  5. Review (5)
  6. Correspondence (3)
  7. Research Letter (3)
  8. Book Whole (1)
  9. Conference Paper (1)
Groups
  1. Department of Medicine (905)
  2. GSK Faculty (905)
  3. Melanoma and Immunotherapeutics Service (905)
  4. Solid Tumor Oncology Division (905)
  5. Melanoma Disease Management Team (222)
  6. Sloan Kettering Institute Postdocs (195)

More Groups

People
  1. Taha Merghoub (230)
  2. Michael Postow (158)
  3. Alan Houghton (118)
  4. Margaret Callahan (113)
  5. Paul Chapman (107)
  6. Katherine Panageas (92)

More People

Years
  1. 2024 (2)
  2. 2023 (15)
  3. 2022 (46)
  4. 2021 (42)
  5. 2020 (46)
  6. 2019 (47)

More Years

Publications
  1. Journal of Clinical Oncology (171)
  2. Journal for ImmunoTherapy of Cancer (81)
  3. Cancer Research (59)
  4. Clinical Cancer Research (35)
  5. Annals of Oncology (34)
  6. European Journal of Cancer (23)

More Publications

Publishers
  1. American Society of Clinical Oncology (171)
  2. American Association for Cancer Research (130)
  3. Biomed Central Ltd (83)
  4. Elsevier Inc. (72)
  5. Nature Publishing Group (52)
  6. Oxford University Press (44)

More Publishers

Results (905)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab
    Meeting Abstract

    Schindler, K.; Harmankaya, K.; Kuk, D.; Mangana, J.; Michielin, O.; Hoeller, C.; Dummer, R.; Pehamberger, H.; Wolchok, J. D.; Postow, M. A.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL)
    Meeting Abstract

    Ribas, A.; Hodi, F. S.; Kefford, R.; Hamid, O.; Daud, A.; Wolchok, J. D.; Hwu, W. J.; Gangadhar, T. C.; Patnaik, A.; Joshua, A. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation positive unresectable or metastatic melanoma (MM)
    Meeting Abstract

    Puzanov, I.; Callahan, M. K.; Linette, G. P.; Patel, S. P.; Luke, J. J.; Sosman, J. A.; Wolchok, J. D.; Hamid, O.; Minor, D. R.; Orford, K. W.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • T-cell receptor (TCR) DNA deep sequencing to evaluate clonality of tumor-infiltrating lymphocytes (TILs) in early stage breast cancer patients (pts) receiving preoperative cryoablation (cryo) and/or ipilinournab (ipi)
    Meeting Abstract

    Page, D. B.; Diab, A.; Yuan, J. D.; Dong, Z. W.; Emerson, R.; Robins, H.; Redmond, D.; Zhao, C. J.; Mu, Z. Y.; Wong, P.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475
    Meeting Abstract

    Kefford, R.; Ribas, A.; Hamid, O.; Robert, C.; Daud, A.; Wolchok, J. D.; Joshua, A. M.; Hodi, F. S.; Gangedher, T. C.; Hersey, P.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475
    Meeting Abstract

    Joseph, R. W.; Elassaiss-Schaap, J.; Wolchok, J. D.; Joshua, A. M.; Ribas, A.; Hodi, F. S.; Hamid, M.; Robert, C.; Daud, A.; Hwu, W. J.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Ipilimumab in acral melanoma: A retrospective review
    Meeting Abstract

    Johnson, D. B.; Peng, C.; Abramson, R. G.; Wolchok, J. D.; Sosman, J. A.; Carvajal, R. D.; Ariyan, C. E.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475
    Meeting Abstract

    Hodi, F. S.; Ribes, A.; Daud, A.; Hamid, O.; Robert, C.; Kefford, R.; Hwu, W. J.; Gangadhar, T. C.; Joshua, A. M.; Hersey, P.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL)
    Meeting Abstract

    Hamid, O.; Robert, C.; Ribas, A.; Wolchok, J. D.; Hodi, F. S.; Kefford, R.; Joshua, A. M.; Hwu, W. J.; Gangadhar, T. C.; Patnaik, A.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safely results from the EORTC 18071 phase III trial
    Meeting Abstract

    Eggerrnont, A. M.; Chiarion-Sileni, V.; Grob, J. J.; Dummer, R.; Wolchok, J. D.; Schmidt, H.; Hamid, O.; Robert, C.; Ascierto, P. A.; Richards, J. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save